Skip to main content
    F

    Fulgent Genetics Inc (FLGT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.07
    -0.59 (-2.37%)

    Market Cap: $688.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fulgent Genetics Inc (FLGT) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Fulgent Genetics (FLGT) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, Fulgent Genetics reported EPS of -$0.09, above the -$0.65 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    62%(24/39)
    Avg Surprise
    +44.58%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.69
    RangeN/A
    3 analysts
    Revenue Consensus
    $89.96M
    Range$86.44M - $92.61M
    3 analysts
    Reports Apr 29, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.33
    Range-$0.33 - -$0.33
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.50+34.0%
    60d ago-$0.50+34.0%
    30d ago-$0.50+34.0%
    7d ago-$0.50+34.0%
    Current-$0.33
    Revenue Consensus
    $89.00M
    Range$89.00M - $89.00M
    1 analysts

    Next Report

    FLGT has an expected report date of Feb 25, 2027.

    FLGT Earnings Call

    The latest FLGT earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, FLGT beat 24, missed 11 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $90.41M, up 7.5% from $84.07M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.09-$0.65-$0.65 - -$0.65+86.15%Beat-164.3%10 up, 0 downNov 5, 2026$90.41M
    Jun 30, 2026-$0.88-$0.79N/A-11.39%Miss-1357.1%20 up, 1 downJul 30, 2026$85.39M
    Mar 31, 2026-$0.36-$0.35-$0.51 - -$0.19-2.86%Miss-1000.0%20 up, 0 downMay 1, 2026$71.14M
    Dec 31, 2025$0.16-$0.06N/A+365.78%Beat+300.0%31 up, 1 downFeb 27, 2026$83.34M
    Sep 30, 2025$0.14-$0.22-$0.27 - -$0.19+163.64%Beat-54.8%30 up, 2 downNov 7, 2025$84.07M
    Jun 30, 2025$0.07-$0.18-$0.23 - -$0.10+138.89%Beat-53.3%31 up, 1 downAug 1, 2025$81.80M
    Mar 31, 2025$0.04-$0.18-$0.23 - -$0.14+122.22%BeatN/A31 up, 1 downMay 2, 2025$73.46M
    Dec 31, 2024$0.04-$0.37-$0.61 - -$0.13+110.84%Beat-85.7%21 up, 0 downFeb 28, 2025$76.21M
    Sep 30, 2024$0.31-$0.15-$0.19 - -$0.09+306.67%BeatN/A30 up, 0 downNov 8, 2024$71.74M
    Jun 30, 2024$0.15-$0.30-$0.34 - -$0.28+150.00%BeatN/A30 up, 0 downAug 2, 2024$71.03M
    Mar 31, 2024-$0.01-$0.32-$0.35 - -$0.30+96.88%BeatN/A30 up, 0 downMay 3, 2024$64.48M
    Dec 31, 2023$0.28-$0.29-$0.37 - -$0.23+196.55%BeatN/A30 up, 0 downFeb 28, 2024$70.50M
    Sep 30, 2023-$0.39-$0.32-$0.35 - -$0.31-21.88%Miss-750.0%20 up, 0 downNov 3, 2023$84.69M
    Jun 30, 2023-$0.08-$0.33-$0.33 - -$0.32+75.76%Beat-110.3%30 up, 0 downAug 4, 2023$67.85M
    Mar 31, 2023-$0.22-$0.43-$0.55 - -$0.34+48.84%Beat-104.3%30 up, 0 downMay 5, 2023$66.17M
    Dec 31, 2022-$0.48-$0.56-$0.57 - -$0.54+14.29%Beat-114.4%30 up, 0 downFeb 28, 2023$67.70M
    Sep 30, 2022$0.06$0.06-$0.06 - $0.170.00%In line-98.5%20 up, 0 downNov 7, 2022$105.66M
    Jun 30, 2022$0.78$0.73$0.73 - $0.73+6.85%Beat-69.9%10 up, 0 downAug 4, 2022$125.34M
    Mar 31, 2022$5.08$3.86$3.40 - $4.32+31.61%Beat-22.1%21 up, 0 downMay 3, 2022$320.27M
    Dec 31, 2021$3.34$2.61$2.49 - $2.67+27.97%Beat-46.1%31 up, 0 downFeb 23, 2022$251.67M
    Sep 30, 2021$3.93$3.25N/A+20.92%Beat+88.9%20 up, 0 downNov 9, 2021$227.87M
    Jun 30, 2021$2.59$2.67$2.57 - $2.93-3.00%Miss+1423.5%3N/AAug 9, 2021$153.62M
    Mar 31, 2021$6.52$5.70$5.41 - $6.17+14.39%BeatN/A3N/AMay 6, 2021$359.43M
    Dec 31, 2020$6.20$4.05$3.54 - $4.41+53.09%Beat+15400.0%3N/AMar 4, 2021$294.98M
    Sep 30, 2020$2.08$0.55$0.44 - $0.67+278.18%Beat+1385.7%3N/ANov 9, 2020$101.72M
    Jun 30, 2020$0.17$0.01-$0.05 - $0.01N/AN/A+183.3%2N/AAug 4, 2020$17.27M
    Mar 31, 2020-$0.03$0.02$0.02 - $0.02-250.00%MissN/A1N/AMay 4, 2020$7.75M
    Dec 31, 2019$0.04$0.04$0.02 - $0.060.00%In lineN/A2N/AMar 10, 2020$8.39M
    Sep 30, 2019$0.14$0.03$0.02 - $0.04+366.67%BeatN/A2N/ANov 4, 2019$10.35M
    Jun 30, 2019$0.06-$0.03N/A+300.00%BeatN/A2N/AAug 5, 2019$8.42M
    Mar 31, 2019-$0.06-$0.02-$0.03 - -$0.01-200.00%MissN/A2N/AMay 7, 2019$5.37M
    Dec 31, 2018-$0.01-$0.01-$0.04 - $0.010.00%In lineN/A2N/AFeb 28, 2019$5.67M
    Sep 30, 2018-$0.03-$0.02-$0.04 - -$0.01-65.00%MissN/A2N/ANov 6, 2018$5.63M
    Jun 30, 2018-$0.01-$0.03-$0.05 - -$0.01+66.67%Beat-150.0%2N/AAug 6, 2018$5.40M
    Mar 31, 2018-$0.06-$0.04-$0.06 - -$0.01-50.00%Miss-300.0%2N/AMay 7, 2018$4.65M
    Dec 31, 2017-$0.06-$0.01-$0.02 - $0.00-500.00%Miss-200.0%2N/AFeb 28, 2018$4.28M
    Sep 30, 2017-$0.02$0.02$0.02 - $0.03-200.00%Miss-118.2%3N/ANov 6, 2017$4.50M
    Jun 30, 2017$0.02$0.02$0.01 - $0.020.00%In lineN/A3N/AAug 7, 2017$4.64M
    Mar 31, 2017$0.03$0.06N/A-50.00%MissN/AN/AN/AMay 8, 2017$5.31M
    Dec 31, 2016$0.06$0.04N/A+50.00%BeatN/AN/AN/AFeb 27, 2017$5.85M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.41, down 16.3% from the year before. It was $0.17 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.41-16.3%
    Dec 31, 2024$0.49N/A
    Dec 31, 2023-$0.41-107.5%
    Dec 31, 2022$5.44-66.8%
    Dec 31, 2021$16.38+94.5%
    Dec 31, 2020$8.42+4577.8%
    Dec 31, 2019$0.18N/A
    Dec 31, 2018-$0.11N/A
    Dec 31, 2017-$0.03-117.6%
    Dec 31, 2016$0.17N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,900 words across 6 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,8896
    2026Q2Jun 30, 20263,8516
    2026Q1Mar 31, 20264,8637
    2025Q4Dec 31, 20256,4098
    2025Q3Sep 30, 20255,0828
    2025Q2Jun 30, 20254,4988
    2025Q1Mar 31, 20254,4668
    2024Q4Dec 31, 20246,0468

    2026Q3 Earnings Call

    Opening remarks

    Lauren Sloane Investor Relations Representative Good afternoon, and welcome to Fulgent's third quarter 2026 financial results conference call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; and Brandon Perthuis, Chief Commercial Officer. The company's press release discussing the financial results is available on the Investor Relations section of the company's website, ir.fulgentgenetics.com. A replay of this call will be available shortly after the call concludes on the Investor Relations section of the company's website. Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. These forward-looking statements represent management's estimates based on current views, expectations, and assumptions, which may prove to be incorrect. As a result, matters discussed in any forward-looking statements are subject to risks, uncertainties, and changes in circumstances that may cause actual results to differ from those described in the forward-looking statements. The company assumes no obligation to update any of the forward-looking statements it may make today to reflect actual results or changes in expectations. Listeners should not rely on any forward-looking statements as predictions of future events and should listen to management's remarks today with the understanding that actual events, including the company's actual future results, may be materially different from what is described in or implied by these forward-looking statements. Please review the more detailed discussions related to these forward-looking statements, including the discussions of some of the risk factors that may cause results to differ from those described in the forward-looking statements, contained in the company's filings with the Securities and Exchange Commission, including the previously filed 10-K for the year ended December 31, 2025, and subsequently filed reports, which are available on the company's Investor Relations website. Management's remarks, including discussions of non-GAAP profit and loss, operating expense, margin, earnings and earnings per share, and adjusted EBITDA, contain financial measures not prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Management has presented these non-GAAP financial measures because it believes they may be useful for investors for various reasons, but these measures should not be viewed as a substitute for or superior to the company's financial results in accordance with GAAP. Please see the company's press release discussing its financial results for the third quarter of 2026 for more information, including the description of how the company calculates non-GAAP income and loss, non-GAAP earnings and loss per share, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating profit and loss and margin, and adjusted EBITDA, and a reconciliation of these financial measures to income and loss, earnings and loss per share, and operating margin, the most directly comparable GAAP financial measures.

    Frequently Asked Questions About FLGT

    When is Fulgent Genetics's next earnings date?

    Fulgent Genetics's next earnings report is expected for Feb 25, 2027.

    Did FLGT beat earnings estimates last quarter?

    Yes. Fulgent Genetics reported EPS of -$0.09 for the quarter ended Sep 30, 2026, above the -$0.65 estimate, a 86.15% surprise.

    What EPS do analysts expect from FLGT next quarter?

    The consensus EPS estimate for Fulgent Genetics for the quarter ending Dec 31, 2026 is -$0.69 from 3 analysts.

    How often does FLGT beat earnings estimates?

    Fulgent Genetics beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +121.66%.